Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/lutris-pharma-appoints-life-sciences-and-pharmaceutical-entrepreneur-moshe-mori-arkin-to-its-board-of-directors-302103595.html
https://www.prnewswire.com/news-releases/lutris-pharma-receives-fda-orphan-drug-designation-for-lut014-for-the-treatment-of-egfri-induced-acneiform-rash-302073499.html
https://www.prnewswire.com/news-releases/lutris-pharma-announces-publication-of-positive-data-from-its-phase-12-trial-of-lut014-to-treat-radiation-dermatitis-in-patients-with-breast-cancer-302066519.html
https://www.prnewswire.com/news-releases/lutris-pharma-presents-data-from-a-real-world-analysis-of-skin-toxicity-from-egfr-inhibitors---an-unmet-challenge-at-the-2023-american-academy-of-dermatology-annual-meeting-301774371.html
https://www.prnewswire.com/news-releases/lutris-pharma-to-present-at-the-16th-annual-european-life-sciences-ceo-forum-in-march-301748031.html
https://www.prnewswire.com/news-releases/lutris-pharmas-founder-and-chairman-of-the-board-receives-5-0-million-grant-from-the-california-institute-of-regenerative-medicine-cirm-to-develop-lut017-for-wound-healing-301656807.html
https://www.prnewswire.com/news-releases/lutris-pharma-receives-notice-of-allowance-for-key-us-patent-application-covering-lead-compound-lut014-a-novel-b-raf-inhibitor-301583710.html
https://www.prnewswire.com/news-releases/lutris-pharma-appoints-company-founder-antoni-ribas-md-phd-as-chairman-of-the-board-of-directors-301543340.html
https://www.prnewswire.com/news-releases/lutris-pharma-initiates-part-two-of-its-phase-12-trial-of-lut014-to-treat-radiation-dermatitis-in-breast-cancer-patients-301389817.html
https://www.prnewswire.com/news-releases/lutris-pharma-doses-first-us-patients-in-phase-2-trial-of-lut014----a-topical-gel-for-the-reduction-of-dose-limiting-acneiform-lesions----in-metastatic-colorectal-cancer-patients-treated-with-egfr-inhibitor-therapy-301346759.html